Home › Trial NCT00377429
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
- Trial IDNCT00377429
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorNeovii Biotech
- Enrollment47
- Start date2006-09
- ConditionsOvarian Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.